Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BAY1214784 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BAY1214784 | EXPERIMENTAL | Dose 1 to 7 of BAY1214784 |
| Placebo | PLACEBO_COMPARATOR | Placebo Dose 1 to 7 of BAY1214784 |
| Name | Type | Description |
|---|---|---|
| BAY1214784 | DRUG | Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form |
| Placebo | DRUG | Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form |
Inclusion Criteria: * Healthy female subjects * Age 45 to 65 years * Body mass index (BMI) above/equal 20 and below/equal 30 kg/m2 * Postmenopausal state Exclusion Criteria: * Incompletely cured pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimi...
BAY1214784 is an investigational small molecule being studied in neurology. It was evaluated in a first-in-human Phase 1 clinical trial in healthy volunteers to assess its safety, tolerability, and pharmacokinetics. The drug is not approved and remains in clinical development.
BAY1214784 is being developed by Bayer AG, a multinational pharmaceutical company. Bayer's stock is traded over-the-counter under the ticker BAYRY.
BAY1214784 is in Phase 1 clinical development. A single Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities.
BAY1214784 has one completed clinical trial, registered as NCT02212080. This was a first-in-human study in healthy volunteers in Germany, designed to investigate the drug's safety, tolerability, and pharmacokinetics. The trial enrolled 48 female participants aged 45 years and older.
Yes, BAY1214784 was studied in healthy volunteers. The completed Phase 1 trial, NCT02212080, enrolled 48 healthy female participants in Germany. The study was randomized, double-blind, and placebo-controlled, focusing on safety, tolerability, and pharmacokinetics.